» Articles » PMID: 35917833

Artificial Intelligence (AI)-based Decision Support Improves Reproducibility of Tumor Response Assessment in Neuro-oncology: An International Multi-reader Study

Abstract

Background: To assess whether artificial intelligence (AI)-based decision support allows more reproducible and standardized assessment of treatment response on MRI in neuro-oncology as compared to manual 2-dimensional measurements of tumor burden using the Response Assessment in Neuro-Oncology (RANO) criteria.

Methods: A series of 30 patients (15 lower-grade gliomas, 15 glioblastoma) with availability of consecutive MRI scans was selected. The time to progression (TTP) on MRI was separately evaluated for each patient by 15 investigators over two rounds. In the first round the TTP was evaluated based on the RANO criteria, whereas in the second round the TTP was evaluated by incorporating additional information from AI-enhanced MRI sequences depicting the longitudinal changes in tumor volumes. The agreement of the TTP measurements between investigators was evaluated using concordance correlation coefficients (CCC) with confidence intervals (CI) and P-values obtained using bootstrap resampling.

Results: The CCC of TTP-measurements between investigators was 0.77 (95% CI = 0.69,0.88) with RANO alone and increased to 0.91 (95% CI = 0.82,0.95) with AI-based decision support (P = .005). This effect was significantly greater (P = .008) for patients with lower-grade gliomas (CCC = 0.70 [95% CI = 0.56,0.85] without vs. 0.90 [95% CI = 0.76,0.95] with AI-based decision support) as compared to glioblastoma (CCC = 0.83 [95% CI = 0.75,0.92] without vs. 0.86 [95% CI = 0.78,0.93] with AI-based decision support). Investigators with less years of experience judged the AI-based decision as more helpful (P = .02).

Conclusions: AI-based decision support has the potential to yield more reproducible and standardized assessment of treatment response in neuro-oncology as compared to manual 2-dimensional measurements of tumor burden, particularly in patients with lower-grade gliomas. A fully-functional version of this AI-based processing pipeline is provided as open-source (https://github.com/NeuroAI-HD/HD-GLIO-XNAT).

Citing Articles

Early characterization and prediction of glioblastoma and brain metastasis treatment efficacy using medical imaging-based radiomics and artificial intelligence algorithms.

Moreau N, Valable S, Jaudet C, Dessoude L, Thomas L, Herault R Front Oncol. 2025; 15:1497195.

PMID: 39949753 PMC: 11821606. DOI: 10.3389/fonc.2025.1497195.


Current state and promise of user-centered design to harness explainable AI in clinical decision-support systems for patients with CNS tumors.

Prince E, Mirsky D, Hankinson T, Gorg C Front Radiol. 2025; 4:1433457.

PMID: 39872709 PMC: 11769936. DOI: 10.3389/fradi.2024.1433457.


Leptomeningeal metastatic disease: new frontiers and future directions.

Ozair A, Wilding H, Bhanja D, Mikolajewicz N, Glantz M, Grossman S Nat Rev Clin Oncol. 2024; 22(2):134-154.

PMID: 39653782 DOI: 10.1038/s41571-024-00970-3.


Repurposing the Public BraTS Dataset for Postoperative Brain Tumour Treatment Response Monitoring.

Sorensen P, Ladefoged C, Larsen V, Andersen F, Nielsen M, Poulsen H Tomography. 2024; 10(9):1397-1410.

PMID: 39330751 PMC: 11436089. DOI: 10.3390/tomography10090105.


The Iterative Design Process of an Explainable AI Application for Non-Invasive Diagnosis of CNS Tumors: A User-Centered Approach.

Prince E, Hankinson T, Gorg C IEEE Workshop Vis Anal Healthc. 2024; 2023:7-13.

PMID: 38989292 PMC: 11235084. DOI: 10.1109/vahc60858.2023.00008.


References
1.
Zerka F, Barakat S, Walsh S, Bogowicz M, Leijenaar R, Jochems A . Systematic Review of Privacy-Preserving Distributed Machine Learning From Federated Databases in Health Care. JCO Clin Cancer Inform. 2020; 4:184-200. PMC: 7113079. DOI: 10.1200/CCI.19.00047. View

2.
Ellingson B, Bendszus M, Boxerman J, Barboriak D, Erickson B, Smits M . Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro Oncol. 2015; 17(9):1188-98. PMC: 4588759. DOI: 10.1093/neuonc/nov095. View

3.
Wen P, Chang S, van den Bent M, Vogelbaum M, Macdonald D, Lee E . Response Assessment in Neuro-Oncology Clinical Trials. J Clin Oncol. 2017; 35(21):2439-2449. PMC: 5516482. DOI: 10.1200/JCO.2017.72.7511. View

4.
OConnor J, Aboagye E, Adams J, Aerts H, Barrington S, Beer A . Imaging biomarker roadmap for cancer studies. Nat Rev Clin Oncol. 2016; 14(3):169-186. PMC: 5378302. DOI: 10.1038/nrclinonc.2016.162. View

5.
Rieke N, Hancox J, Li W, Milletari F, Roth H, Albarqouni S . The future of digital health with federated learning. NPJ Digit Med. 2020; 3:119. PMC: 7490367. DOI: 10.1038/s41746-020-00323-1. View